Dynamics of the human gut microbiome in inflammatory bowel disease

Jonas Halfvarson, Colin J Brislawn, Regina Lamendella, Yoshiki Vázquez-Baeza, William A Walters, Lisa M Bramer, Mauro D'Amato, Ferdinando Bonfiglio, Daniel McDonald, Antonio Gonzalez, Erin E McClure, Mitchell F Dunklebarger, Rob Knight, Janet K Jansson, Jonas Halfvarson, Colin J Brislawn, Regina Lamendella, Yoshiki Vázquez-Baeza, William A Walters, Lisa M Bramer, Mauro D'Amato, Ferdinando Bonfiglio, Daniel McDonald, Antonio Gonzalez, Erin E McClure, Mitchell F Dunklebarger, Rob Knight, Janet K Jansson

Abstract

Inflammatory bowel disease (IBD) is characterized by flares of inflammation with a periodic need for increased medication and sometimes even surgery. The aetiology of IBD is partly attributed to a deregulated immune response to gut microbiome dysbiosis. Cross-sectional studies have revealed microbial signatures for different IBD subtypes, including ulcerative colitis, colonic Crohn's disease and ileal Crohn's disease. Although IBD is dynamic, microbiome studies have primarily focused on single time points or a few individuals. Here, we dissect the long-term dynamic behaviour of the gut microbiome in IBD and differentiate this from normal variation. Microbiomes of IBD subjects fluctuate more than those of healthy individuals, based on deviation from a newly defined healthy plane (HP). Ileal Crohn's disease subjects deviated most from the HP, especially subjects with surgical resection. Intriguingly, the microbiomes of some IBD subjects periodically visited the HP then deviated away from it. Inflammation was not directly correlated with distance to the healthy plane, but there was some correlation between observed dramatic fluctuations in the gut microbiome and intensified medication due to a flare of the disease. These results will help guide therapies that will redirect the gut microbiome towards a healthy state and maintain remission in IBD.

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1. Defining a healthy plane
Figure 1. Defining a healthy plane
Diagram summarizing the procedure for creating a representative plane for a group of samples S: a, sample selection, b, model fitting and c, distance calculations for all samples. The healthy plane is then located in UniFrac space by d, fitting a line to the major axis of the points, and e, defining a least-squares fit to identify a plane that minimizes the sum of squares of distances to the nearest point on the plane. f, Verification that the position of the healthy plane is not driven by proteobacteria-dominated outliers: Procrustes Analysis comparing original samples and those with Proteobacteria removed. A vector connects each original sample (red) with the same samples after Proteobacteria have been omitted (black). p < 0.001, M2 = 0.018, 999 permutations. g, The short length of most vectors indicates that the relative composition of most samples does not change when proteobacteria are filtered out.
Figure 2. The gut microbiomes of different…
Figure 2. The gut microbiomes of different IBD subtypes display different distributions relative to a healthy plane (HP)
a, Median distances from HP for each IBD subtype. All IBD subtypes were significantly different from healthy controls (GLM, all p < 0.00261). b, UniFrac distances between subsequent samples. c, Distance to HP for each individual patient. HP was defined using data shown in Supplemental Video 1. See Supplementary Table 1 for composition of downstream analysis cohort. Boxes show interquartile range (IQR). Whiskers denote the lowest and highest values within 2.5 × IQR of the median. Circles represent outliers.
Figure 3. Correlation between fecal calprotectin concentrations…
Figure 3. Correlation between fecal calprotectin concentrations and distance to a defined healthy plane (HP) in 3D ordination space
Data represent a correlation of f-calprotectin levels and distance to the here defined healthy plane in 3D ordination space (see Supplementary Video 1) for each individual and time point for different inflammatory bowel disease (IBD) subtypes. To compare the relationship between f-calprotectin and the healthy plane, a generalized linear mixed effects model was fit, with a conditional Gamma distribution, using f-calprotectin and disease type as fixed effects and including a random subject effect; f-calprotectin was not significant (p = 0.27501).
Figure 4. Microbiome dynamics of selected individuals…
Figure 4. Microbiome dynamics of selected individuals from each IBD subtype and a healthy control
From each IBD subtype and healthy control group, representative individuals sampled over the most time points and having complete clinical and sequence data were selected. Data represent f-calprotectin values, distance to the healthy plane, and Shannon diversity and rarified abundances of most common taxa at the family level. Note that taxa unclassified at the family level are represented in the ‘f__’ category.

References

    1. Eckburg PB, et al. Diversity of the Human Intestinal Microbial Flora. Science. 2005;308:1635–1638.
    1. Costello EK, et al. Bacterial Community Variation in Human Body Habitats Across Space and Time. Science. 2009;326:1694–1697.
    1. Human Microbiome Consortium. Structure Function and Diversity of the Healthy Human Microbiome. Nature. 2012;486:207–214.
    1. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.
    1. Martínez I, et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 2013;7:269–280.
    1. Flores GE, et al. Temporal variability is a personalized feature of the human microbiome. Genome Biol. 2014;15:531.
    1. Zaura E, et al. Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces. mBio. 2015;6:e01693–1615.
    1. Sokol H, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–16736.
    1. Willing B, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease. Inflamm Bowel Dis. 2009;15:653–660.
    1. Willing BP, et al. A Pyrosequencing Study in Twins Shows That Gastrointestinal Microbial Profiles Vary With Inflammatory Bowel Disease Phenotypes. Gastroenterology. 2010;139:1844–1854.e1.
    1. Gevers D, et al. The treatment-naïve microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392.
    1. Rajca S, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis. 2014;20:978–986.
    1. Wills ES, et al. Fecal Microbial Composition of Ulcerative Colitis and Crohn’s Disease Patients in Remission and Subsequent Exacerbation. PLoS ONE. 2014;9
    1. Young VB, et al. Multiphasic analysis of the temporal development of the distal gut microbiota in patients following ileal pouch anal anastomosis. Microbiome. 2013;1:9.
    1. Martinez C, et al. Unstable Composition of the Fecal Microbiota in Ulcerative Colitis During Clinical Remission. Am J Gastroenterol. 2008;103:643–648.
    1. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.
    1. Caporaso JG, et al. Moving pictures of the human microbiome. Genome Biol. 2011;12:R50.
    1. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599–608.
    1. Lewis JD. The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology. 2011;140:1817–1826.e2.
    1. Kolho KL, et al. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. Am J Gastroenterol. 2015;110:921–930.
    1. Rooks MG, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 2014;8:1403–1417.
    1. Sipponen T, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.
    1. Breiman L. Random Forests. Mach Learn. 45:5–32.
    1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15
    1. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.
    1. Knights D, Parfrey LW, Zaneveld J, Lozupone C, Knight R. Human-associated microbial signatures: examining their predictive value. Cell Host Microbe. 2011;10
    1. Silverberg MS, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol J Can Gastroenterol. 2005;19(Suppl A):5A–36A.
    1. EMP DNA Extraction Protocol. 2011
    1. Caporaso JG, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A. 2011;108:4516–4522.
    1. Caporaso JG, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–336.
    1. Kopylova E, Noé L, Touzet H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics. 2012;28:3211–3217.
    1. McDonald D, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6:610–618.
    1. Lozupone C, Knight R. UniFrac: a New Phylogenetic Method for Comparing Microbial Communities. Appl Environ Microbiol. 2005;71:8228–8235.
    1. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-throughput microbial community data. GigaScience. 2013;2:16.
    1. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. J Comput Graph Stat. 1996;5:299.
    1. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS ONE. 2013;8:e61217.
    1. Liaw A, Wiener M. Classification and Regression by randomForest. R News. 2002;2:18–22.
    1. Oksanen J, et al. vegan: Community Ecology Package. 2016.

Source: PubMed

3
订阅